Collegium Pharmaceutical, Inc. filings document regulatory disclosures for a commercial biopharmaceutical company with ADHD and pain-management medicines. Form 8-K reports cover operating results, earnings presentations, Regulation FD materials, guidance, material agreements, capital-structure matters and clinical or regulatory disclosures tied to the company's product portfolio.
Proxy materials describe shareholder voting matters, board composition, director nominations, board succession, executive compensation and governance practices. The filing record also captures product-related risk disclosures and formal public-company reporting for Collegium's Nasdaq-listed common stock.
Collegium Pharmaceutical (COLL) reported that it released its financial results for the quarter ended September 30, 2025. The company furnished a press release and an earnings presentation alongside this update.
The materials were provided as exhibits to an 8-K: Exhibit 99.1 (press release) and Exhibit 99.2 (earnings presentation). Both exhibits were furnished under Items 2.02 and 7.01. COLL’s common stock trades on the NASDAQ Global Select Market.
Thomas B. Smith, EVP and Chief Medical Officer of Collegium Pharmaceutical, Inc. (COLL) reported the sale of 17,478 shares of the company's common stock on 08/29/2025 at a weighted-average price of $38.4241 per share. After the reported disposition, the reporting person beneficially owned 70,264 shares, held directly. The Form 4 was filed as a single-person report and signed by an attorney-in-fact, Colleen Tupper, on 09/03/2025. The footnote states the reported price is a weighted average for multiple transactions that ranged from $38.37 to $38.48 and that the filer can provide per-price breakdowns on request.
Collegium Pharmaceutical, Inc. (COLL) Form 144 notice: An insider plans to sell 17,478 shares of common stock through Merrill Lynch, with an aggregate market value of $671,576.38. The shares represent vested restricted stock units acquired on 02/21/2025 and were transferred to a brokerage account the same day. The filing lists the approximate sale date as 08/29/2025 and identifies NASDAQ as the exchange. The filer reports no securities sold in the past three months and includes the standard signer representation that no undisclosed material adverse information is known.
Scott Dreyer, EVP & Chief Commercial Officer of Collegium Pharmaceutical, Inc. (COLL), reported contemporaneous option exercise and market sale executed under a Rule 10b5-1 trading plan. On 08/18/2025 he exercised a stock option to acquire 16,389 shares at an exercise price of $21.34 per share, and the same day sold 16,389 shares in multiple transactions at a weighted average price of $38.2068, reducing his reported beneficial ownership to 103,613 shares. The option exercised is fully vested and exercisable and expires on 02/05/2030. The Form 4 notes the transactions were effected pursuant to a 10b5-1 plan adopted August 28, 2024, and a power of attorney was used to file the report.
Insider transactions reported for Collegium Pharmaceutical, Inc. (COLL)
Director Gino Santini filed a Form 4 reporting transactions on 08/15/2025. The filing shows acquisition of 15,000 shares of common stock at a price of $13.45 (reported with code M) and a sale of 5,405 shares at a weighted-average price of $37.1912. Following the reported acquisition the filing lists 100,447 shares beneficially owned, and following the sale it lists 95,042 shares beneficially owned. The filing also references a stock option with a $13.45 exercise price related to 15,000 underlying shares and states the option is fully vested and exercisable. The signature on the form is by an attorney-in-fact on 08/19/2025.
Form 144 notice for Collegium Pharmaceutical, Inc. (COLL): An insider filed a proposed sale of 16,389 common shares to be brokered through Fidelity Brokerage Services LLC on 08/18/2025 with an aggregate market value of $626,170.29. The filing reports 31,502,127 shares outstanding and lists the exchange as NASDAQ. The securities reported were acquired under an option granted on 02/05/2020 and are noted as acquired on 08/18/2025, with payment indicated as cash. The filing also discloses a prior sale by Scott Dreyer of 4,861 shares on 08/13/2025 for gross proceeds of $184,880.84. The notice includes the standard representation that the seller does not possess undisclosed material adverse information.
Scott Dreyer, EVP & Chief Commercial Officer of Collegium Pharmaceutical (COLL), reported paired option exercise and share sale transactions on 08/13/2025 executed under a Rule 10b5-1 trading plan adopted August 28, 2024. He exercised a fully vested option to purchase 4,861 shares at an exercise price of $21.34 per share and concurrently sold 4,861 shares at a weighted-average price of $38.0335 per share (sales ranged $38.00–$38.10). After these transactions Dreyer beneficially owned 103,613 common shares and held options covering 16,389 shares. The Form 4 was signed by an attorney-in-fact on behalf of Dreyer on 08/15/2025.
Rubric Capital Management LP and David Rosen reported the sale of 25,000 shares of Collegium Pharmaceutical, Inc. (COLL) on 08/13/2025 at a weighted average price of $37.85 per share, with transaction prices ranging from $37.71 to $38.10. After the sale, the Reporting Persons collectively beneficially own 3,132,743 shares indirectly through funds/accounts managed by Rubric Capital.
The Form 4 clarifies Rubric Capital is the investment adviser to the reporting vehicles and Mr. Rosen is the managing member of the general partner; the filing disclaims beneficial ownership except to the extent of any pecuniary interest. The Reporting Persons offer to provide detailed per-price sale breakdowns to the issuer or SEC staff upon request.
Collegium Pharmaceutical, Inc. (COLL) Form 3 disclosure: Rubric Capital Management LP and David E. Rosen filed an initial Section 16 ownership report disclosing indirect beneficial ownership of 3,157,743 shares of Collegium common stock. Rubric Capital is the investment adviser to the funds/accounts holding the shares (the "Rubric Vehicles"). Mr. Rosen is the Managing Member of the general partner of Rubric Capital. The filing includes an express disclaimer that the reporting persons do not admit beneficial ownership except to the extent of any pecuniary interest.
Collegium Pharmaceutical, Inc. (COLL) filed a Form 144 reporting a proposed sale of 5,405 shares of common stock to be executed through Fidelity Brokerage Services LLC on 08/15/2025 on NASDAQ, with an aggregate market value of $201,018.82 and total shares outstanding listed as 31,502,127. The filing indicates the shares are being sold for cash.
The table shows the securities were associated with an option grant dated 09/10/2015; the acquisition and sale dates are both listed as 08/15/2025. No other sales in the past three months are reported, and the filer certifies they are unaware of undisclosed material adverse information about the issuer.